Upcoming AWS Coverage on Baxter International Post-Earnings Results
LONDON, UK / ACCESSWIRE / January 11, 2017 / Active Wall St. blog coverage looks at the headline from Teleflex Inc. (NYSE: TFX) as the Company announced on January 10, 2017, the FDA 510(k) Clearance to commercialize its Arrow® VPS Rhythm™ Device with Optional TipTracker™ Technology in the United States. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
One of Teleflex's competitors within the Medical Instruments & Supplies space, Baxter International Inc. (NYSE: BAX) announced on January 06, 2017, that it will host a quarterly conference call to discuss its Q4 2016 financial results on Wednesday, February 01, 2017, at 7:30 a.m. CT. AWS will be initiating a research report on Baxter International in the coming days following its earnings release.
Today, AWS is promoting its blog coverage on TFX; touching on BAX. Get all of our free blog coverage and more by clicking on the links below:
http://www.activewallst.com/registration-3/?symbol=TFX
http://www.activewallst.com/registration-3/?symbol=BAX
What is Arrow® VPS Rhythm?
Teleflex stated that the Arrow® VPS Rhythm Device assists in placement and confirmation of a catheter tip in the SVC-CAJ (superior vena-cava-cavoatrial junction) and can be used with a broad range of catheter types and brands. Intravascular P-wave changes are saved as the catheter approaches the SVC, helping to identify the lower 1/3 of the SVC, near the CAJ, eliminating the need for confirmatory chest X-ray or fluoroscopy in adult patients. When paired with the single-use TipTracker™ Stylet for insertion of peripherally-inserted central catheters (PICCs), the Arrow® VPS Rhythm™ Device provides real-time visual navigation by tracing the catheter pathway with a blue line on a color-screen. The Device boasts an expansive sphere of visual navigation to provide easy navigation of the PICC during insertion.
"This clearance positions us to provide catheter tip placement solutions that meet customer's unique therapeutic and budgetary needs," said Jay White, president and general manager, Vascular Division of Teleflex, "The VPS Rhythm™ Device with Optional TipTracker™ Technology will complement our existing Arrow® VPS G4™ Device, diversifying and strengthening our catheter tip positioning portfolio globally. Most importantly, it furthers our goal of making products that simplify clinician's work and improve a patient's care."
Launches LMA® Gastro™ Airway
In a separate press release on the same day, Teleflex announced the launch of the new LMA® Gastro™ Airway with Cuff Pilot™ Technology – the first laryngeal mask specifically designed to facilitate esophageal access and promote airway control during endoscopic procedures.
Teleflex stated that moderate-to-deep sedation during endoscopy is a common practice around the world, however, respiratory depression from sedative drugs and airway obstruction requiring intervention are known risks associated with endoscopic procedures, with studies demonstrating that hypoxemia can occur in 11%-50% of cases. The Company noted that in the United States there are more than 6.9 million upper endoscopies performed annually and many of these are undertaken without an airway management device in place. The LMA® Gastro™ Airway is designed to maintain a patent airway throughout the procedure to support patient safety, in adult patients undergoing endoscopic procedures.
Teleflex noted that the LMA® Gastro™ Airway also features Cuff Pilot™ Technology – an integrated, cuff pressure indicator that constantly monitors cuff pressure, detecting changes resulting from fluctuations in temperature, nitrous oxide levels and movements within the airway. It provides at-a-glance feedback, highlighting changes that could affect patient safety.
Justin McMurray, President of the Teleflex Anaesthesia & Emergency Medicine Division stated:
"Our LMA® Brand revolutionized airway management with the development of the original laryngeal mask airway. We are excited to continue this tradition with the introduction of the LMA® Gastro™ Airway to empower clinicians to achieve airway control during endoscopic."
Stock Performance
On January 10th, 2017, Teleflex's share price finished the trading session at $167.88, rising 1.76%. A total volume of 381.63 thousand shares exchanged hands. The stock has advanced 7.20% and 34.40% in the last month and past twelve months, respectively. Furthermore, since the start of the year, shares of the Company have gained 4.18%. The stock is trading at a PE ratio of 30.12 and has a dividend yield of 0.81%. The stock currently has a market cap of $7.39 billion.
Active Wall Street:
Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
AWS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active Wall Street
ReleaseID: 452564
